Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase)in Patients With Pancreatic Cancer

Inclusion Criteria:

* Exocrine pancreatic adenocarcinoma cytologically or histologically confirmed
* Locally advanced and non-resectable with invasion of the superior mesenteric artery (stage III) or metastatic (stage IV) as defined by TNM (primary tumor, regional nodes, metastasis) 2002 classification (UICC 2002)
* resistant to a first or second line chemotherapy with gemcitabine
* Patient aged between 18 to 70 years
* Signed Informed Consent Form
* Life expectancy ≥ 12 weeks
* Accurate measurement of tumor volume by imagery (in at least one dimension)
* Presence of one or several tumor markers (carcinoembryonic antigen \[CEA\] and cancer antigen \[CA\] 19.9)
* Eastern Cooperative Oncology Group \[ECOG\] Prognostic Score : 0, 1 or 2
* Patient beneficiary of a Social Security Insurance

Exclusion Criteria:

* Patient with an endocrine or acinar pancreatic tumor
* Patient with known or suspected cerebro-meningeal metastases
* Haemoglobin level greater than 13 g/L
* Patient hypersensitive to L-asparaginase or have had prior exposure to any form of L-asparaginase
* Splenic vein thrombosis \< 3 months or under active treatment
* Anti-vitamin K treatment
* Hepatic Insufficiency unrelated to pancreatic cancer
* Renal insufficiency unrelated to pancreatic cancer
* Pancreatitis or pancreatitis history unrelated to pancreatic cancer
* Insulin-dependant diabetes mellitus unrelated to pancreatic cancer
* Current or prior coagulopathy disorders unrelated to pancreatic cancer
* ECOG Prognostic Score 3 or 4
* History of grade 3 blood transfusion reaction (life threatening situation)
* Presence of rare and dangerous anti-erythrocyte antibodies preventing from getting a compatible packed Red Blood Cells for the patient
* Patient already included in another clinical trial
* Pregnancy, breast-feeding or absence of secured contraception
* Unwillingness to sign the informed consent form